March 02, 2015 10:55 AM ET

Biotechnology

Company Overview of Accera, Inc.

Company Overview

Accera, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies for treating central nervous systems disorders, primarily neurodegenerative diseases. The company’s product pipeline includes therapeutic treatments for Parkinson's and Alzheimer's diseases, and other age-related memory loss disorders. Its products include Axona, a prescription-only medical food product for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease; and AC-1204 that targets the metabolic deficiencies and imbalances associated with Alzheimer’s disease by providing ketone bodies as an alternative energy source for ...

380 Interlocken Crescent

Interlocken Advanced Technology Park

Suite 780

Broomfield, CO 80021

United States

Founded in 2001

Phone:

303-999-3700

Fax:

303-999-3799

Key Executives for Accera, Inc.

Chief Executive Officer, President and Director
Founder
Age: 58
Vice President of Finance, Secretary and Controller
Vice President of Research & Development
Vice President of Commercial Development
Compensation as of Fiscal Year 2014.

Accera, Inc. Key Developments

Accera, Inc. and University of Miami Announce Collaboration to Study Axona for Cognitive Impairment in Patients with Multiple Sclerosis

Accera, Inc. announced a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis. Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease. Drs. Melissa Ortega and Heather Katzen, two researchers at the Miller School, will serve as the primary investigators of the study. The project will be funded by Fast Forward, LLC, a nonprofit organization established by the National Multiple Sclerosis Society. More than 2.1 million people are affected by MS worldwide, and cognitive problems commonly occur in individuals with MS. Symptoms vary in severity and may have a negative impact on relationships, work and quality of life. There are few treatment options available and there is a pressing need for new interventions for cognitive impairment in MS. The UM Miller School of Medicine and Accera, with support from Fast Forward, LLC, will be testing Axona as a unique strategy for improving cognitive function in individuals with MS to address this disabling symptom.

Similar Private Companies By Industry

Company Name Region
Aonori Aquafarms, Inc. United States
Analytical Stem Cell Corp. United States
Kellbenx Inc. United States
Blue Angel Holdings Corporation United States
Apollo Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Accera, Inc., please visit www.accerapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.